Public Company Leaders
Publicly traded AI drug discovery platforms with validated pipelines
Recursion Pharmaceuticals
AI-powered drug discovery combining cellular imaging, automation, and machine learning. $1B+ raised. Acquired Cyclica, Valence Discovery. Nvidia partnership.
Schrödinger
Physics-based molecular simulation platform. Powers drug discovery at major pharma. Computational chemistry pioneer.
Exscientia
AI-driven drug design. First AI-designed drugs in clinical trials. Multiple Big Pharma partnerships. Oxford spinout.
AbCellera
AI-powered antibody discovery. Single-cell technology platform. Discovered bamlanivimab (COVID-19 therapy).
Generative AI Pioneers
Companies using generative AI models to design novel molecules
Insilico Medicine
Pharma.AI platform with Chemistry42 and Biology42. First fully AI-designed drug to enter Phase 2 (IPF). Hong Kong headquarters.
Isomorphic Labs
Alphabet/DeepMind spinout. AlphaFold technology for drug discovery. $3B+ Eli Lilly and Novartis deals.
Generate Biomedicines
Generative biology platform. Diffusion models for protein design. Flagship Pioneering company. $450M+ raised.
EvolutionaryScale
ESM-3 protein language model. Meta AI spinout. Programmable biology. $142M Series A.
AI Target Discovery Platforms
Companies using AI to identify and validate drug targets
Insitro
Machine learning for drug discovery. Founded by Daphne Koller. Roche, Gilead partnerships. $743M raised.
BenevolentAI
Benevolent Platform for target identification. AstraZeneca partnership. London-based, SPAC merged (AMS: BAI).
Valo Health
Opal computational platform. Clinical data analytics. Acquired Tara Biosystems. Flagship company.
Relay Therapeutics
Dynamo platform combining MD simulations and machine learning. Protein motion analysis. NASDAQ: RLAY.
AI-Designed Drugs in Clinical Trials
Companies with AI-designed molecules advancing through human trials
Clinical Pipeline Milestones
Phase 2 for IPF. First AI-designed drug for AI-discovered target in Phase 2.
Phase 1 A2A antagonist. First AI-designed immuno-oncology molecule.
Phase 2 for Cerebral Cavernous Malformation. Repurposed via AI.
IND-enabling studies. First diffusion-designed protein therapeutic.
Biology + AI Platforms
Companies combining wet lab biology with AI for closed-loop discovery
Quris AI
Bio-AI clinical prediction platform. Patient-on-chip integrated with machine learning for toxicity prediction.
Automata
Laboratory automation for AI-driven drug discovery. LINQ cloud platform. UK robotics company.
Phenomic AI
AI-powered drug discovery using cell morphology. Deep learning on cellular images. Recursion competitor.
Arctoris
Ulysses platform for automated drug discovery. Cloud lab for AI-driven research. Oxford spinout.
Sector Analysis
Market Overview
- + AI drug discovery market projected to reach $8.9B by 2030 (40% CAGR)
- + 15+ AI-designed drugs have entered clinical trials as of 2025
- + All top 20 pharma companies have AI drug discovery partnerships
- + Average time from target to IND reduced from 4+ years to 12-18 months
- + AlphaFold and large language models transforming protein design
Explore More Categories
Discover companies across all human-relevant technology sectors